UNSPSC 51184006: Glicaramide

This classification denotes an anti-diabetic agent with the molecular formula C30H42N6O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) UK5SR22C8Q, chemically known as 1-cyclohexyl-3-((p-(2-(1-ethyl-4-(isopentyloxy)-3-methyl-1h-pyrazolo(3,4-b)pyridine-5-carboxamido)ethyl)phenyl)sulfonyl)urea but more generally known as glicaramide, which bears US NIH Compound Identifier 65799. European Medicines Agency schedules Glicaramide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07919MIG.

UNSPSC 51184006 Glicaramide, a Commodity code, encompasses pharmaceutical products — specifically generic medications and over-the-counter drugs — that state and local government facilities procure through cooperative purchasing agreements and direct vendor contracts. State and local buyers under this code include state health agencies and multistate purchasing cooperatives administering contracts on behalf of participating state and local government entities. The scope of procurement emphasizes generic multi-source pharmaceuticals with detailed product specifications tied to National Drug Codes, SKUs, UPCs, and manufacturing locations, alongside compliance requirements including current Good Manufacturing Practices certification, Drug Supply Chain Security Act adherence, and FDA approval. Vendors typically contract through authorized pharmaceutical wholesalers using chargeback systems and offer pricing flexibility through formats such as fixed price, net price (NF30, NF60, NF90), or WAC-minus structures.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the most recent substantial activity under this code. MMCAP issued a Request for Proposal (Solicitation S1070000015802, posted January 20, 2026, with responses due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products serving participating state and local government facilities across multiple states including Oregon. The procurement required vendors to supply products through three authorized wholesalers — AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC — with awarded vendors to be provided to wholesalers by May 15, 2026 and resulting agreements effective July 1, 2026. Evaluation weighted price competitiveness at 75 percent, with 10 percent on fixed pricing, 5 percent each on administrative fee data format compliance, EDI capability, and agreement to a 3 percent administrative fee. Vendors required $5 million commercial general liability, $2 million network security and privacy liability, and $2 million professional liability coverage, with contract terms of two years for new responders and optional extensions at MMCAP's discretion.